GEA advances freeze-drying manufacturing with €80 million pharmaceutical technology centre
GEA’s new 40,000-square-metre facility in Elsdorf, Germany represents a strategic expansion into pharmaceutical freeze-drying systems, addressing surging global demand for vaccine and injectable drug manufacturing technologies. The investment demonstrates significant industry confidence in lyophilisation technology advancement.
German engineering company GEA has secured partial approval for its €80 million pharmaceutical technology centre in Elsdorf, North Rhine-Westphalia, marking a pivotal advancement in freeze-drying system manufacturing capabilities. The facility, spanning more than 40,000 square metres, positions the company to meet escalating global demand for lyophilisation equipment crucial to vaccine and injectable pharmaceutical production.
First freeze-dryer components installed at new facility
Following July 2025 regulatory approval, GEA has commenced relocating operations from its previous Hürth location to the purpose-built Elsdorf site. The delivery and installation of initial product chambers – core components where the freeze-drying process occurs – represents a significant operational milestone in the facility’s development.
The new competence and production centre will primarily focus on manufacturing freeze-drying systems utilised worldwide for injectable drug production, including vaccines. Complete relocation of production, storage, laboratory areas, and administrative functions is scheduled for completion during the fourth quarter of 2025.
Sustainability and digitisation integrated into manufacturing design
The “Factory of the Future” concept emphasises environmental responsibility through integrated photovoltaic systems providing renewable electricity, waste heat recycling, and green roof installations promoting biodiversity. Advanced warehouse management systems and digital workflows enhance operational efficiency and transparency throughout the manufacturing process.
Strategic early access approach accelerates timeline
Partial approval enables GEA’s engineering teams to commence assembly operations whilst construction continues in other facility areas. This phased approach allows early-stage assembly of complex systems, eliminating potential time-consuming component relocations and ensuring project completion within budget parameters.
The facility represents GEA’s second “Factory of the Future” implementation, accommodating all 250 permanent employees from the previous location. The investment underscores the strategic importance of pharmaceutical sector growth and technological innovation in freeze-drying applications.
The new building incorporates the highest sustainability standards, including autonomous energy generation and carbon neutrality targets, alongside innovative digital solutions spanning the entire pharmaceutical manufacturing value chain.
